Corn zearalenone-degrading enzyme mutant and its encoding gene, recombinant vector, recombinant strain and application
By introducing specific amino acid mutations into zearidenone degrading enzymes, mutants with higher thermal stability and acid resistance are formed, the problem of insufficient thermal stability and acid resistance of existing enzymes is solved, and efficient zearidenum is achieved Enone degradation effect, suitable for industrial applications.
Patent Information
- Application Number
- CN202410049452.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-12
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-01-12
AI Technical Summary
The existing zearalenone degrading enzymes have weak thermal stability and poor acid resistance, which are difficult to meet the needs of industrial applications.
By introducing specific mutation points (positions 67, 72, 73 and 176) into the amino acid sequence of the zearidenone degrading enzyme, mutants are formed to improve their thermal stability and acid resistance, for example, Glutamine mutations into valine, lysine mutations into alanine, arginine mutations into aspartic acid, valine mutations into phenylalanine, forming P450 (K72A/Q67V/V176F/R73N) mutations body.
The enzyme activity of the mutant is maintained at 37°C for more than 60%, the optimum temperature rises to 45-50°C, and the acid resistance is significantly improved. It can effectively catalyze the degradation of zearalenone, and is suitable for industrial applications.
Smart Images

Figure BDA0004662398860000121
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a corn zearalenone degrading enzyme mutant and its encoding gene, recombinant vector, recombinant strain and application. Background Art
[0002] Mycotoxins are toxic secondary metabolites produced by molds during their growth, mainly including aflatoxins, trichothecenes, zearalenone, ochratoxin A and fumonisin. Grains and other raw materials will be contaminated by molds in the field. If the ambient temperature and humidity are suitable during transportation, processing and storage, the mold will continue to grow and the toxin content will increase. According to estimates by the Food and Agriculture Organization of the United Nations, 25% of the world's grains are contaminated by mycotoxins each year, and an average of 2% are inedible; in addition, diseases and deaths caused by animal poisoning due to toxin pollution cause huge economic losses to the grain industry and animal husbandry.
[0003] Zearalenone (ZEN), also known as F-2 toxin, was isolated by Stob et al. from corn contaminated by fusarium graminearum, Fusarium luteum and Fusarium graminearum. Fusarium graminearum is both parasitic and saprophytic, with strong ecological adaptability and wide distribution. Corn, wheat, barley and oats are easily infected by Fusarium and contaminated by ZEN when they become moldy. Animals absorb ZEN by eating feed contaminated by ZEN. ZEN has an estrogen-like effect. It can compete with estrogen in the body to bind to the corresponding receptors, activate downstream response elements, and induce estrogen receptor dimerization, thereby producing a series of estrogen-like effects, causing estrogen levels in animals to be disordered, and damaging the reproductive system of animals, especially sows. The main manifestations are decreased appetite, immunosuppression and slow growth. Continuous poisoning can cause reproductive disorders in female livestock, infertility, miscarriage and stillbirth. ZEN is also highly carcinogenic and can affect human edible meat and dairy products through animal ingestion, posing a serious threat to human health.
[0004] In order to prevent ZEN from entering the food chain through feed, food raw materials, etc., in addition to increasing the supervision and inspection of feed, food raw materials, etc., some methods can also be used to reduce or remove ZEN. The methods for degrading ZEN and its derivatives mainly include chemical methods, physical methods and biological methods; the chemical method mainly uses strong acids and alkalis such as ozone, hydrogen peroxide, sodium carbonate and other chemical reagents to react with ZEN to convert it into other low-toxic or even non-toxic substances; the physical method mainly involves high temperature method, radiation method, high pressure method and adsorption method, etc. However, these technologies are only partially effective and cannot completely remove ZEN, and their industrial applications are hindered by their high cost and low efficiency. Chemical and physical treatments can also destroy the nutritional components of grains and feeds and introduce secondary pollution. In contrast, biological methods have the advantages of environmental protection, high efficiency, low cost, and more importantly, they will not cause secondary pollution to food or feed raw materials. Therefore, this method shows great prospects in the food and feed industry.
[0005] Biological methods mainly include microbial adsorption and enzyme degradation. For microbial adsorption, studies have found that the main component of the cell wall of fungi such as yeast and lactic acid bacteria is peptidoglycan, which is connected by glycosidic bonds to form a network structure on the surface of the cell wall, which has a significant adsorption effect on fungal toxins such as ZEN. The biological enzyme degradation method mainly involves enzymes (lactone hydrolases, proteases, and peroxidases, etc.) produced by microbial metabolism, which can destroy the structure of ZEN through hydrolysis or oxidation, converting it into low-toxic or non-toxic substances.
[0006] However, the existing zearalenone-degrading enzymes have problems such as weak thermal stability and poor acid resistance, which makes it difficult to meet the needs of industrial applications. If this problem can be effectively solved, it will be of great significance to the reduction and removal of zearalenone. Summary of the invention
[0007] The purpose of the present invention is to overcome the problems existing in the prior art and provide a zearalenone degrading enzyme mutant and its encoding gene, recombinant vector, recombinant strain and application. The zearalenone degrading enzyme mutant not only has efficient zearalenone degradation activity, but also has strong thermal stability and good acid resistance.
[0008] In order to achieve the above-mentioned purpose, the first aspect of the present invention provides a zearalenone degrading enzyme mutant of corn, which comprises a mutation at the R site compared with the protein having an amino acid sequence as shown in SEQ ID NO: 1; the R site is selected from at least one of the 67th, 72nd, 73rd and 176th positions.
[0009] Preferably, compared with the protein with the amino acid sequence shown in SEQ ID NO: 1, the mutant comprises at least one of a mutation of glutamine at position 67 to valine, a mutation of lysine at position 72 to alanine, a mutation of arginine at position 73 to aspartic acid, and a mutation of valine at position 176 to phenylalanine.
[0010] Preferably, the amino acid sequence of the mutant is shown in SEQ ID NO:2.
[0011] The second aspect of the present invention provides a gene encoding a zearalenone-degrading enzyme mutant, wherein the gene has a nucleotide sequence encoding the above-mentioned zearalenone-degrading enzyme mutant.
[0012] Preferably, the gene has a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO:2.
[0013] Preferably, the nucleotide sequence of the gene is shown in SEQ ID NO:3.
[0014] The third aspect of the present invention provides a recombinant vector, which contains the above-mentioned gene.
[0015] Preferably, the expression vector of the recombinant vector is a pET series plasmid.
[0016] The fourth aspect of the present invention provides a recombinant strain, which contains the above-mentioned gene or the above-mentioned recombinant vector.
[0017] Preferably, the host strain of the recombinant strain is Escherichia coli and / or Bacillus subtilis.
[0018] Preferably, the host strain of the recombinant strain is Escherichia coli BL21 (DE3).
[0019] The fifth aspect of the present invention provides the use of at least one of the above-mentioned zearalenone-degrading enzyme mutant, the above-mentioned gene, the above-mentioned recombinant vector and the above-mentioned recombinant strain in degrading zearalenone.
[0020] The sixth aspect of the present invention provides a method for degrading zearalenone, which comprises the following steps: contacting zearalenone with at least one of the above-mentioned zearalenone degrading enzyme mutant, the above-mentioned gene, the above-mentioned recombinant vector and the above-mentioned recombinant strain.
[0021] Preferably, the contacting conditions include: a temperature of 45-50° C. and a pH of 4-6.
[0022] Through the above technical scheme, the beneficial effects of the present invention are as follows: the zearalenone degrading enzyme mutant provided by the present invention has strong thermal stability and structural stability, and the enzyme activity is maintained at more than 60% after being kept at 37°C for 8 hours; the optimum temperature of the multi-point mutant rises to 45-50°C, which is more than 10°C higher than that of the wild-type enzyme, and the acid resistance is significantly improved; under the optimal catalytic conditions, the relative enzyme activity of the zearalenone degrading enzyme mutant provided by the present invention in catalyzing the degradation of zearalenone does not decrease significantly, and this discovery has important research value for the industrial degradation of zearalenone. DETAILED DESCRIPTION
[0023] The endpoints and any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.
[0024] The first aspect of the present invention provides a corn zearalenone degrading enzyme mutant, characterized in that the mutant comprises a mutation at the R site compared to the protein having an amino acid sequence as shown in SEQ ID NO: 1; the R site is selected from at least one of the 67th, 72nd, 73rd and 176th positions.
[0025] During the research process, the inventors of the present invention unexpectedly discovered that the zearalenone degrading enzyme based on the amino acid sequence shown in SEQ ID NO: 1 is used as a wild-type enzyme (hereinafter referred to as P450 wild enzyme), and an amino acid residue is substituted at a certain position R (position 67, position 72, position 73 and position 176) on the amino acid sequence of the wild-type enzyme. The obtained zearalenone degrading enzyme mutant (P450 mutant) can effectively improve thermal stability and structural stability, and has strong acid resistance, while being able to maintain strong zearalenone degradation activity, which has important research value for the industrial degradation of zearalenone.
[0026] In the present invention, the amino acid sequence of the wild-type P450 enzyme shown in SEQ ID NO: 1 is: MNEQIPHDKSLDNSLTLLKEGYLFIKNRTERYNSDLFQARLLGKNFICMTGAEAAKVFYDTNRFQRVNALPANVQKSLFGVNAIVGMDGSAHIHRAMLFLSLMTPPHQKRLAELMTEEWKAAVTRWEKADQVVLFEEAKEILCWVACYWAGVPLKETEVKERADDFIDMFDAFGAVGPRHWKGRRARPRAEEWIEVMIED VRAGLLKTPAGTALHEMAFHKQEDGSELDSRMAAIELINVLRPIVAISYFLVFSALALHEHPKYKEWLRSGSCRKREMFVQEVRRYYPFGPFLGAIVKKDFVWNNCEFKK GTSVLLDVYGTNHDPRLWDHPDEFRPERFAEREENPFDLIPQGGGHAEKGHRCPGEGITIEVMKASLDFLVNQIEYDVPEQSLHYSLARMPSLPESGFIMSGIRQKR(SEQ ID NO: 1).
[0027] According to the present invention, preferably, the mutant comprises at least one of a mutation of glutamine at position 67 to valine, a mutation of lysine at position 72 to alanine, a mutation of arginine at position 73 to aspartic acid, and a mutation of valine at position 176 to phenylalanine compared to the protein having an amino acid sequence as shown in SEQ ID NO: 1. The inventors have found that under this preferred embodiment, it is beneficial to further enhance the degradation activity of the mutant on zearalenone, and improve thermal stability, structural stability and acid tolerance.
[0028] According to the present invention, further preferably, the glutamine at position 67 of the protein shown in the amino acid sequence SEQ ID NO: 1 is mutated to valine, the lysine at position 72 is mutated to alanine, the arginine at position 73 is mutated to aspartic acid, and the valine at position 176 is mutated to phenylalanine, forming a mutant P450 (K72A / Q67V / V176F / R73N) with an amino acid sequence such as SEQ ID NO: 2. The optimum temperature of the multi-point mutant rises to 45-50°C, which is more than 10°C higher than that of the wild-type enzyme, and the acid resistance is significantly improved; under the optimum catalytic conditions, the relative enzyme activity of catalytic degradation of zearalenone does not decrease significantly.
[0029] According to the present invention, there is no particular limitation on the method for obtaining the P450 mutant, as long as a P450 mutant having an amino acid sequence with the above characteristics can be obtained. For example, the P450 mutant can be obtained by artificial synthesis, or by obtaining its encoding gene through the amino acid sequence of the mutant and then performing corresponding biological expression to obtain it.
[0030] The second aspect of the present invention provides a gene encoding a zearalenone-degrading enzyme mutant, wherein the gene has a nucleotide sequence encoding the above-mentioned zearalenone-degrading enzyme mutant.
[0031] In the present invention, any gene capable of encoding and expressing the above-mentioned P450 mutants belongs to the protection scope of the present invention. It is well known to those skilled in the art that genetic codons are degenerate. Therefore, in the case of understanding the amino acid sequence of the above-mentioned P450 mutants, those skilled in the art can obtain genes with different nucleotide sequences and capable of encoding the above-mentioned P450 mutants according to conventional technical means. For example, according to the coding gene of the P450 wild enzyme (for example, the coding gene with a nucleotide sequence as shown in SEQ ID NO: 4), the codon encoding the amino acid at the site can be adjusted accordingly according to the change of the amino acid at the mutation site. For another example, according to the characteristics of the expression host, the coding gene can also be optimized to improve the expression amount and / or expression efficiency of the P450 mutant.
[0032] According to the present invention, preferably, the gene has a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 2. Further preferably, the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 2 is shown in SEQ ID NO: 3. The inventors found that under this preferred embodiment, it is beneficial to further improve the thermal stability, structural stability and acid tolerance of the P450 mutant.
[0033] The nucleotide sequences provided by the present invention can usually be obtained by polymerase chain reaction (PCR) amplification, recombination, or artificial synthesis. Once the relevant nucleotide sequence is obtained, the relevant amino acid sequence can be obtained in large quantities by recombination. The obtained nucleotide sequence is usually cloned into a vector, then transferred into genetically engineered bacteria, and then the relevant nucleotide sequence is isolated from the propagated host cells by conventional methods.
[0034] In addition, the relevant nucleotide sequences can also be synthesized by known artificial chemical synthesis methods.
[0035] The third aspect of the present invention provides a recombinant vector, which contains the above-mentioned gene.
[0036] In the present invention, the expression vector used in the recombinant vector can be selected from various vectors known in the art, such as various commercially available plasmids, cosmids, phages and retroviruses, etc. The preferred expression vector of the present invention is a pET series plasmid, such as a pET-24a plasmid. The construction method of the recombinant vector can adopt various methods commonly used in the art, such as connecting the target gene to the expression vector after enzyme digestion.
[0037] The fourth aspect of the present invention provides a recombinant strain, which contains the above-mentioned gene or the above-mentioned recombinant vector.
[0038] The method for constructing the recombinant strain can be accomplished by conventional technical means in the art, for example, by introducing a vector into which a target gene is inserted into the corresponding strain.
[0039] In the present invention, any host cell such as an engineered bacterium that can be used to express foreign genes in the art can be used to construct the recombinant strain provided by the present invention, as long as it can express the SerAP450 mutant described in the present invention. The host cell can be a prokaryotic cell or a eukaryotic cell, preferably a prokaryotic cell, such as Escherichia coli, Bacillus subtilis, etc.
[0040] According to the present invention, preferably, the host strain of the recombinant strain is Escherichia coli. There is no special requirement for the type of Escherichia coli used to construct the recombinant strain, and it can be various Escherichia coli commonly used in the art that can express the target gene. Further preferably, the host strain of the recombinant strain is Escherichia coli BL21 (DE3). The inventors found that under this preferred embodiment, it is beneficial to further improve the expression efficiency of the P450 mutant.
[0041] The zearalenone degrading enzyme mutant provided by the present invention can not only efficiently catalyze and degrade zearalenone, but also has strong thermal stability and good acid resistance. The fifth aspect of the present invention provides the use of at least one of the above-mentioned zearalenone degrading enzyme mutant, the above-mentioned gene, the above-mentioned recombinant vector and the above-mentioned recombinant strain in degrading zearalenone.
[0042] The sixth aspect of the present invention provides a method for degrading zearalenone, which comprises the following steps: contacting zearalenone with at least one of the above-mentioned zearalenone degrading enzyme mutant, the above-mentioned gene, the above-mentioned recombinant vector and the above-mentioned recombinant strain.
[0043] In the present invention, the zearalenone-degrading enzyme mutant can be obtained by fermenting and purifying the recombinant strain; wherein the fermentation culture can adopt a conventional culture medium, such as LB culture medium.
[0044] Exemplarily, the recombinant strain can be inoculated into an LB medium containing kanamycin at an inoculation amount of 0.2-0.8 volume%, and shake-cultured for 10-15 hours at a temperature of 35-40°C and a rotation speed of 180-220rpm to obtain a seed solution; the seed solution is inoculated into an LB medium containing kanamycin at an inoculation amount of 4-8 volume%, and shake-cultured for 0.5-1.5 hours at a temperature of 35-40°C and a rotation speed of 180-220rpm, and IPTG is added for induction, and the culture is continued at a temperature of 10-20°C and a rotation speed of 180-220rpm for 10-20 hours to obtain a fermentation liquid; the fermentation liquid is subjected to solid-liquid separation and the supernatant is removed, the bacterial precipitate is diluted with PBS, ultrasonically disrupted, and solid-liquid separation is performed again, and the supernatant is filtered with a 0.45μm microporous filter membrane for standby use to obtain a crude enzyme solution of the zearalenone degrading enzyme mutant of the corn; the crude enzyme solution is eluted and purified to obtain a pure enzyme solution of the zearalenone degrading enzyme mutant of the corn. At this time, the pure enzyme solution of the zearalenone-degrading enzyme mutant can be directly used as an enzyme preparation, or processed into a corresponding enzyme preparation.
[0045] In the present invention, solid-liquid separation can be carried out by any conventional separation method, such as centrifugation, filtration, etc.
[0046] In the present invention, the contacting may be mixing the pure enzyme solution of the zearalenone degrading enzyme mutant with zearalenone to catalyze the degradation of zearalenone. Preferably, the contacting conditions include: a temperature of 45-50°C and a pH of 4-6, so that the zearalenone degrading enzyme mutant performs degradation under the most suitable catalytic conditions and has a higher degradation activity.
[0047] The present invention will be described in detail below through examples.
[0048] In the following examples, unless otherwise specified, the reagents and raw materials used are conventional commercially available products.
[0049] In the following examples, the formula of LB medium is: yeast extract 5g / L; tryptone 10g / L; sodium chloride 10g / L, and the pH of the medium is 7.0;
[0050] In the following examples, the definition of enzyme activity (U) is: the amount of enzyme required to degrade 1 μg of substrate zearalenone within 1 min is regarded as one enzyme activity unit U;
[0051] Relative enzyme activity refers to the ratio of the activity of a certain enzyme to the activity of a standard enzyme under certain conditions.
[0052] Example 1 Preparation method of P450 mutant
[0053] (1) The wild-type P450 enzyme (nucleotide sequence as shown in SEQ ID NO: 4, amino acid sequence as shown in SEQ ID NO: 1) was connected to the multiple cloning site of pET-24a to obtain the wild-type plasmid pET-24a-P450 wild-type enzyme;
[0054] (2) Construction of pET-24a-P450(K72A) / P450(Q67V) / P450(V176F) / P450(R73N) single-point mutation plasmid: Quick Change method was used for site-directed mutagenesis. The single-point mutants to be constructed included: mutating the lysine at position 72 of the P450 wild enzyme to alanine to form P450 (K72A), mutating the glutamine at position 67 of the P450 wild enzyme to valine to form P450 (Q67V), mutating the valine at position 176 of the P450 wild enzyme to phenylalanine to form P450 (V176F), and mutating the arginine at position 73 of the P450 wild enzyme to aspartic acid to form P450 (R73N). The sequencing verification results showed that no random mutations occurred except the required mutation sites, and the mutant plasmids pET-24a-P450 (K72A), pET-24a-P450 (V176F), pET-24a-P450 (Q67V) and pET-24a-P450 (R73N) were successfully constructed.
[0055] Using the recombinant plasmid pET-24a-P450 wild enzyme as a template, forward and reverse primers were designed. The mutation primers are as follows, with capital letters indicating mutation points:
[0056] K72A-F: 5'-tccagcgggtgaacgctttgcctaagcg-3' (SEQ ID NO: 5);
[0057] K72A-R: 5'-aaagcgttcacccgctggaatcgattc-3' (SEQ ID NO: 6);
[0058] Q67V-F: 5'-tccagcgggtgaacgctttgcctaagcg-3' (SEQ ID NO: 7);
[0059] Q67V-R: 5'-aaagcgttcacccgctggaatcgattc-3' (SEQ ID NO: 8);
[0060] V176F-F: 5'-tcggtgcttttggaccgcggcattg-3' (SEQ ID NO: 9);
[0061] V176F-R: 5'-cgcggtccaaaagcaccgaacgcatcga-3' (SEQ ID NO: 10);
[0062] R73N-F: 5'-tgcctaagaatgtgcagaaatcgctgtttggt-3' (SEQ ID NO: 11);
[0063] R73N-R: 5'-ttctgcacattcttaggcaaagcgttctgcc-3' (SEQ ID NO: 12);
[0064] The total volume of the PCR amplification reaction system was 20 μL, and the composition was shown in Table 1. The reaction procedure was: 98°C, 30 s; 98°C, 10 s; 60°C, 10 s; 72°C, 20 s; 34 cycles; 72°C, 1 min; 4°C.
[0065] Table 1 PCR reaction system composition
[0066] Components Addition amount template 1μL Upstream primer 1μL Downstream primer 1μL Enzymes 10μL Sterile water 7μL
[0067] PCR product nucleic acid electrophoresis verification and template digestion: The PCR product band size was verified by agarose gel electrophoresis. After verification, 1 μL of Q.cut DpnI and 2 μL of Q.cut Buffer (10×) were added to the PCR product system, and the enzyme digestion reaction was carried out at 37°C for 1 hour to remove the wild-type recombinant plasmid in the system. Then, positive clones were picked for plasmid extraction and DNA sequencing. The mutant plasmid that was successfully sequenced was introduced into E. coli BL21 (DE3) competent cells to construct mutant gene recombinant bacteria for the induced expression of mutant enzymes.
[0068] Construction of pET-24a-P450 (K72A / Q67V / V176F / R73N) multi-point mutation plasmid: Using the four single-point mutation recombinant plasmids pET-24a-P450 (K72A), pET-24a-P450 (V176F), pET-24a-P450 (Q67V) and pET-24a-P450 (R73N) constructed in step (2) as templates, forward and reverse primers were designed, and the target fragments containing four mutation sites were combined using the Golden Gate Cloning technology to obtain the combined mutant plasmid pET-24a-P450 (K72A / Q67V / V176F / R73N), wherein the amino acid sequence of P450 (K72A / Q67V / V176F / R73N) is shown in SEQ ID NO: 2, and the nucleotide sequence is shown in SEQ ID NO: 3;
[0069] Golden Gate Cloning was used for seamless cloning, followed by sequencing verification and transformation of the combined mutant plasmids, as well as induced expression and separation and purification of the combined mutant enzymes.
[0070] Example 2 Expression and purification method of P450 mutant enzyme
[0071] The combined mutant plasmid pET-24a-P450 (K72A / Q67V / V176F / R73N) and the wild-type plasmid pET24a-P450 wild enzyme after sequencing verification in Example 1 were transformed into Escherichia coli BL21 (DE3) cells to obtain the corresponding recombinant strains. The two recombinant strains were inoculated into LB medium containing 50 μL of kanamycin solution (concentration of 500 μg / mL) at an inoculum of 200 μL, respectively, and shaken at 37°C and 200 rpm for 12 h to obtain seed liquid; 15 mL of the seed liquid was inoculated into LB medium containing 50 μL of kanamycin solution (concentration of 500 μg / mL), shaken at 37°C and 200 rpm for 1 h, and IPTG (added to a final concentration of 50 μg / mL) was added. ) induction, and continued to culture at a temperature of 16°C and a rotation speed of 200 rpm for 14 hours to obtain a fermentation liquid; the fermentation liquid was centrifuged at 5000 rpm for 10 minutes to remove the supernatant, the bacterial precipitate was diluted with PBS, and ultrasonically disrupted at 360 W for 40 minutes (on 5 seconds and off 5 seconds, 35% power), and then centrifuged at 7500 rpm for 30 minutes at 4°C, and the supernatant was filtered with a 0.45 μm microporous filter membrane for standby use to obtain a crude enzyme solution of a P450 enzyme mutant P450 (K72A / Q67V / V176F / R73N) and a crude enzyme solution of a P450 wild enzyme;
[0072] The crude enzyme solution was passed through a His60 Ni Superflow resin purification column, rinsed with 5 mL of ultrapure water, rinsed with 10 mL of solution B (50 mM Tris-HCl buffer, pH 8.0, 25 mM imidazole, 150 mM NaCl), and finally eluted with 5 mL of solution C (50 mM Tris-HCl buffer, pH 8.0, 500 mM imidazole, 150 mM NaCl), and the eluate was collected; the eluate was then desalted using a desalting column GE HiTrap Desalting, and eluted with solution A (50 mM Tris-HCl buffer, pH 8.0) to obtain pure enzyme solution of P450 enzyme mutant P450 (K72A / Q67V / V176F / R73N) and pure enzyme solution of P450 wild enzyme
[0073] The same method was used to prepare the purified pure enzyme solutions corresponding to the P450 enzyme mutants P450(K72A), P450(V176F), P450(Q67V) and P450(R73N).
[0074] Example 3 Comparison of thermal stability of enzymes before and after mutation
[0075] Each pure enzyme solution obtained in Example 2 was diluted with 50 mM Tris-HCl buffer at pH 8.0, and the enzyme activity was measured using the diluted enzyme solution, which was recorded as the diluted enzyme solution.
[0076] Solution A consists of 50 mM Tris-HCl buffer at pH 8.0 and zearalenone solution. The final concentration of the substrate zearalenone in 0.5 mL of the reaction system is 20 μg / ml.
[0077] Experimental group: The activity assay reaction system was 0.5 mL, which was a mixture of 0.45 mL of solution A and 0.05 mL of diluted enzyme solution; the pH value of the reaction system was 8.0. After the reaction system was incubated at 40°C for 10 min, 0.5 mL of chromatography-grade methanol was used to terminate the reaction. After cooling, the degradation amount of the substrate zearalenone was determined using a high performance liquid chromatography (HPLC).
[0078] After the pure enzyme solutions obtained in Example 2 were diluted to a concentration of about 10 μg / mL, they were incubated at 37°C, 45°C and 50°C, respectively. Samples were taken at regular intervals to perform degradation reactions under the optimal conditions for the enzyme to observe the changes in the enzyme activities of the P450 enzyme mutants and the P450 wild enzyme over time at different temperatures. The enzyme solution that had not been incubated was used as a control (i.e., 100%). The results are shown in Tables 2 and 3.
[0079] Table 2 shows the thermal stability (t 1 / 2) was greatly improved; the relative enzyme activity of mutant P450 (K72A / Q67V / V176F / R73N) at 37°C for 8 hours was 61.1%, which was significantly increased compared with 2.1% of the wild-type P450 enzyme; the relative enzyme activity of mutant P450 (K72A / Q67V / V176F / R73N) at 45°C for 1 hour was 70.9%, which was also significantly increased compared with 5.6% of the wild-type P450 enzyme. Table 3 shows that the relative enzyme activity of mutant P450 (K72A / Q67V / V176F / R73N) at 50°C for 0.5 hours was 77.7%, which was also significantly increased compared with the single-point mutants P450 (K72A), P450 (V176F), P450 (Q67V) and P450 (R73N). This shows that the thermal stability of the mutant P450 (K72A / Q67V / V176F / R73N) has been significantly improved, making it more suitable for industrial production requirements.
[0080] Table 2 Comparison of t1 / 2 and Tm values of wild-type enzyme and mutant enzyme
[0081]
[0082] Table 3 Comparison of residual enzyme activity and Tm value of wild-type enzyme and mutant enzyme stored at 50℃ for 0.5h
[0083] name Residual enzyme activity (%) Tm(℃) Wild-type P450 27.8 47.2 P450(K72A) 42.6 48.6 P450(Q67V) 39.1 49.7 P450(V176F) 67.6 47.8 P450(R73N) 52.8 48.2 P450(K72A / Q67V / V176F / R73N) 77.7 47.0
[0084] Example 4 Comparison of the optimal temperature of the enzyme before and after mutation
[0085] In this example, the effect of temperature on the catalytic activity of mutant enzymes was studied. The P450 enzyme mutant P450 (K72A / Q67V / V176F / R73N) prepared in Example 2 and the P450 wild enzyme were subjected to enzyme reactions at pH 8.0 and different temperatures (30-60°C). The optimum temperature of the multi-point mutant P450 (K72A / Q67V / V176F / R73N) increased to 45-50°C, which was more than 10°C higher than that of the P450 wild enzyme. At the same time, the relative enzyme activity of the multi-point mutant under high temperature conditions of 55°C and 60°C was also significantly improved.
[0086] Table 4 Comparison of the optimal reaction temperature of wild enzyme and mutant enzyme under the optimal reaction conditions
[0087] name Optimum temperature (℃) Wild-type P450 37 P450(K72A / Q67V / V176F / R73N) 45-50
[0088] Example 5 Optimal reaction pH and pH tolerance determination
[0089] Prepare buffer solutions of different pH values, including citric acid-disodium hydrogen phosphate buffer (pH=3.0, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0), Tris-HCl buffer (pH=8.0, 9.0), and glycine-NaOH buffer (pH=10.0, 11.0, 12.0).
[0090] Using zearalenone solution as a substrate, the substrate was mixed with buffer solutions with pH values of 3.0, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, and 9.0, respectively, and the optimal reaction pH of the wild-type P450 enzyme and its mutant P450 (K72A / Q67V / V176F / R73N) was determined at 37°C.
[0091] According to the results of the optimal reaction pH measurement, the optimal pH of the wild-type P450 enzyme is 7, and the optimal pH of the mutant P450 (K72A / Q67V / V176F / R73N) is 6.
[0092] The mutant P450 (K72A / Q67V / V176F / R73N) was diluted with buffer solutions of pH 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, and 12.0 in a concentration gradient until the absorbance of the reaction product was between 0.5 and 1.5. Since the absorbance value was more accurate within this range, the enzyme solution reached this range after being diluted 250 times. 500 μL of the 250-fold diluted enzyme solution was taken out and placed at 37° C. for 1 hour, then taken out and placed on ice to determine the relative residual enzyme activity. The determination conditions were 37° C. and pH=6.
[0093] According to the results of pH tolerance test, after tolerating in a buffer solution with a pH of 4 to 6 for 1 hour, the relative residual enzyme activity of the mutant P450 (K72A / Q67V / V176F / R73N) is about 71-92%, while the relative residual enzyme activity of the P450 wild enzyme only retains about 52-82% of the activity. In particular, after tolerating in a buffer solution with a pH of 4 for 1 hour, the mutant P450 (K72A / Q67V / V176F / R73N) still retains 79% of the activity, while the P450 wild enzyme only retains 53% of the activity; and the relative residual enzyme activity of the mutant P450 (K72A / Q67V / V176F / R73N) at a pH of 8 to 11 is significantly lower than that of the P450 wild enzyme, which shows that the acid resistance of the mutant P450 (K72A / Q67V / V176F / R73N) is significantly improved.
[0094] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention.
Claims
1. A zearalenone-degrading enzyme mutant, characterized in that: The amino acid sequence of the zearalenone degrading enzyme mutant is shown in SEQ ID NO:
2.
2. A gene encoding the zearalenone-degrading enzyme mutant according to claim 1.
3. A recombinant vector, characterized in that: The recombinant vector contains the gene according to claim 2.
4. The recombinant vector according to claim 3, characterized in that: The expression vector of the recombinant vector is a pET series plasmid.
5. A recombinant strain, characterized in that: The recombinant strain contains the gene according to claim 2 or the recombinant vector according to claim 4.
6. The recombinant strain according to claim 5, characterized in that The host strain of the recombinant strain is Escherichia coli or Bacillus subtilis.
7. The recombinant strain according to claim 6, characterized in that The host strain of the recombinant strain is Escherichia coli BL21 (DE3).
8. Use of at least one of the zearalenone-degrading enzyme mutant according to claim 1, the gene according to claim 2, the recombinant vector according to claim 3, and the recombinant strain according to claim 5 in degrading zearalenone.
9. A method for degrading zearalenone, characterized in that: The method comprises the following steps: contacting at least one of the zearalenone degrading enzyme mutant according to claim 1 and the recombinant strain according to claim 5 with zearalenone.
10. The method according to claim 9, characterized in that The contacting conditions include: temperature of 45-50° C. and pH of 4-6.
